A ruling in Jason Miller, et al. v. General Motors, LLC has scrapped the possibility of a class action lawsuit against GM for a BECM failure in the Chevy Volt.

Boston Scientific will face more benign competition than previously feared when it comes to pulsed field ablation, according ...

CardioFocus announced the completion of clinical cases with its QuickShot Nav large-area focal pulsed field ablation (PFA) ...

We recently published a list of the 10 Best Dividend Monarchs to Invest in Now. In this article, we are going to take a look ...

Abbott designed the Volt PFA catheter for maneuverability, efficient ablation and thermal risk mitigation, said Dr.

GAAP diluted EPS of $0.76; adjusted diluted EPS of $1.09 First-quarter reported sales growth of 4.0 percent; organic sales growth of 6.9 percent or ...

Q1 2025 Management View CEO Robert Ford highlighted the robust performance for Q1 2025, with high single-digit sales growth and double-digit earnings per share (EPS) growth. Adjusted EPS for the ...

Q1 2025 Earnings Conference Call April 16, 2025 9:00 AM ETCompany ParticipantsMike Comilla - VP, IRRobert Ford - Chairman ...

Guidance: Abbott reaffirms full-year 2025 adjusted EPS of $5.05-$5.25 versus a consensus of $5.15, with organic sales growth ...

Pulse Biosciences is developing nsPFA technology for cardiac ablation to treat AFib and for ablating benign thyroid nodules.